{"entity":{"id":"nct05227664","kind":"trial","name":"A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer","aka":[],"tldr":"A phase 2 trial of AK117 in triple-negative breast cancer, run by Akeso, active and no longer recruiting.","summary":"A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer is a phase 2 interventional study registered as NCT05227664 by Akeso, with 120 participants enrolled, started 2022-03-23 and due to reach its primary completion in 2026-12-30. Interventions recorded: AK117, AK112, Nab paclitaxel and paclitaxel.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05227664","url":"https://clinicaltrials.gov/study/NCT05227664"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["tnbc"],"sections":[],"technologies":[],"targets":[],"drugs":["ak117"],"companies":["akeso"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05227664","phase":"2","setting":"A Phase II Study of AK117/AK112 in Combination With Chemotherapy for Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer","sponsor":"Akeso","enrolled":120,"outcomes":[]},"route":"/trials/nct05227664/","neighbours":{"cancer":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"drug":[{"id":"ak117","kind":"drug","name":"AK117","route":"/drugs/ak117/"}],"company":[{"id":"akeso","kind":"company","name":"Akeso","route":"/companies/akeso/"}]}}